Skip to main content

Table 4 Common terminology criteria for adverse event (CTCAE) adverse events of transarterial chemoembolization (n = 66)

From: Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis

Abdominal pain

51 (77.3%)

 Grade 1

23 (34.8%)

 Grade 2

15 (22.3)

 Grade 3

13 (19.7%)

Nausea

19 (28.8%)

 Grade 1

19 (28.8%)

 Grade 2

0 (0%)

 Grade 3

0 (0%)

Vomiting

14 (21.2%)

 Grade 1

14 (21.2%)

 Grade 2

0 (0%)

 Grade 3

0 (0%)

Fever

15 (22.3%)

 Grade 1

14 (21.2%)

 Grade 2

1 (1.5%)

 Grade 3

0 (0%)

Alanine aminotransferase increased

50 (75.8%)

 Grade 1

33 (50.0%)

 Grade 2

9 (13.6%)

 Grade 3

8 (12.1%)

Aspartate aminotransferase increased

63 (95.5%)

 Grade 1

21 (31.8%)

 Grade 2

20 (30.3%)

 Grade 3

22 (33.3%)

Anemia

33 (50%)

 Grade 1

20 (30.3%)

 Grade 2

11 (16.7%)

 Grade 3

2 (3.0%)

Neutropenia

0 (0%)

Intra-abdominal infection

4 (6.1%)

 Grade 1

0 (0%)

 Grade 2

0 (0%)

 Grade 3

4 (6.1%)

Cholecystitis

0 (0%)